Genomics

Dataset Information

0

ADAM17 is required for EGF-R induced intestinal tumors via IL-6 trans-signaling


ABSTRACT: Colorectal cancer is treated with antibodies blocking epidermal growth factor receptor (EGF-R) but therapeutic success is limited. EGF-R is stimulated by soluble ligands, which are derived from transmembrane precursors by ADAM17-mediated proteolytic cleavage. In mouse intestinal cancer models in the absence of ADAM17, tumorigenesis was almost completely inhibited and the few remaining tumors were of low grade dysplasia. RNA-Seq analysis demonstrated downregulation of STAT3 and Wnt pathway components. Since EGF-R on myeloid cells, but not on intestinal epithelial cells is required for intestinal cancer and IL-6 is induced via EGF-R stimulation, we analyzed the role of IL-6 signaling. Tumor formation was equally inhibited in IL-6 -/- and sgp130Fc transgenic mice, in which only trans-signaling via soluble IL-6R is abrogated. ADAM17 is needed for EGF-R-mediated induction of IL-6 synthesis, which via IL-6 trans-signaling induces ß-catenin dependent tumorigenesis. Our data reveal the possibility of a novel strategy for treatment of colorectal cancer, which could circumvent intrinsic and acquired resistance to EGF-R blockade.

ORGANISM(S): Mus musculus

PROVIDER: GSE107759 | GEO | 2018/02/19

REPOSITORIES: GEO

Similar Datasets

| PRJNA421311 | ENA
| PRJEB23659 | ENA
2022-10-06 | GSE214666 | GEO
2022-09-18 | PXD030740 | Pride
2022-09-02 | GSE212316 | GEO
2021-04-23 | PXD024502 | Pride
2022-04-20 | GSE199113 | GEO
2017-02-09 | MTBLS240 | MetaboLights
| E-MTAB-7764 | biostudies-arrayexpress
2016-05-03 | GSE80981 | GEO